Determinants of adherence to obesity medication: A narrative review

影响肥胖症药物依从性的因素:一项叙述性综述

阅读:2

Abstract

The increasing prevalence of obesity, complex nature of this chronic disease, and risks of developing obesity-related comorbidities outline the need for sustainable and effective management for people living with obesity. In addition to behavioral interventions, obesity medications (OMs) are increasingly considered an integral part of management of people living with obesity. OM adherence is essential to achieve the health benefits of these medications. Adherence to medications, defined as the process by which patients take their medications as prescribed, is determined by a range of factors and can be broken down into phases: initiation, implementation, and persistence (the persistence phase includes discontinuation/stopping treatment). Obesity-specific challenges exist to optimize OM adherence, which may explain varying OM adherence compared with medication for other chronic diseases (diabetes, hypertension, dyslipidemia, and osteoporosis). However, lessons can be learned from other chronic diseases to improve OM adherence, for example from type 2 diabetes and hypertension. This review aims to provide practical guidance for identifying OM- and obesity-specific determinants of adherence and discusses adherence determinants per adherence phase and obesity management phase (weight gain, weight loss, and weight stabilization/regain). This practical guidance will assist with developing obesity-specific interventions to improve OM adherence. PRACTITIONER POINTS: OMs are increasingly considered as an integral part of obesity management; however, like with all chronic disease medications, low adherence to these medications is often observed, impacting their therapeutic effect. Adherence to obesity medication can be affected at any phase of obesity management (weight gain, weight loss, and weight stabilization/regain) so considering the disease phase can help identify potential reasons for low adherence. Future initiatives to improve adherence to obesity medication should be a key focus of discussions at each opportunity with healthcare professionals, including thorough evaluation and targeted education, all in a supportive and stigma-free manner.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。